Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
11 nov. 2019 06h00 HE
|
Foamix, Ltd.
Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assetsMenlo’s serlopitant for pruritus associated with prurigo nodularis...
Foamix Announces Issuance of New U.S. Patent for Compositions Combining a Retinoid and a Tetracycline Antibiotic
07 nov. 2019 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today...
Foamix Announces Publication of AMZEEQ™ (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology
04 nov. 2019 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, announced today the...
Foamix Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 11
01 nov. 2019 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
Foamix Enters Into Manufacturing and Supply Agreement For AMZEEQ™ and FMX103
23 oct. 2019 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced...
Foamix Announces Settlement of Litigation with Teva Relating to Finacea Foam
21 oct. 2019 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced...
UPDATE -- Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
18 oct. 2019 16h48 HE
|
Foamix, Ltd.
AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline AMZEEQ Offers Efficacy with Low Systemic Absorption REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE...
Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
18 oct. 2019 16h07 HE
|
Foamix, Ltd.
AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline AMZEEQ Offers Efficacy with Low Systemic Absorption REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE...
Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea
17 oct. 2019 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference
10 oct. 2019 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a clinical stage specialty...